Sergio Quezada
Fondateur chez ACHILLES THERAPEUTICS PLC
Fortune : 304 204 $ au 30/06/2024
Postes actifs de Sergio Quezada
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ACHILLES THERAPEUTICS PLC | Directeur Technique/Scientifique/R&D | 01/11/2020 | - |
| Fondateur | 01/11/2020 | - | |
| University College London | Corporate Officer/Principal | 01/01/2011 | - |
Historique de carrière de Sergio Quezada
Anciens postes connus de Sergio Quezada
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Fondateur | 01/05/2016 | - |
Formation de Sergio Quezada
| Dartmouth Medical School | Doctorate Degree |
| Pontificia Universidad Católica de Chile | Undergraduate Degree |
Statistiques
Internationale
| Royaume-Uni | 4 |
| Etats-Unis | 2 |
| Chili | 2 |
Opérationnelle
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Consumer Services | 4 |
| Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
 | Health Technology |
| ACHILLES THERAPEUTICS PLC | Health Technology |
- Bourse
- Insiders
- Sergio Quezada
- Expérience
